Circulating Interleukins as Biomarkers in Non-Small Cell Lung Cancer Patients: A Pilot Study Compared to Normal...

Area of Science:

• Oncology
• Biochemistry
• Molecular Biology

Background:

• Biomarkers are crucial for non-small cell lung cancer (NSCLC) diagnosis and patient stratification.
• Interleukins (ILs) are investigated as potential NSCLC biomarkers.
• Exhaled-breath condensates (EBCs) offer a non-invasive sampling option.

Purpose of the Study:

• To evaluate IL-11, IL-6, IL-8, IL-17A, and IL-33 as biomarkers in NSCLC.
• To compare biomarker levels in NSCLC patients' plasma, sera, and EBCs against healthy controls.
• To validate findings in NSCLC tumor tissues.

Main Methods:

• Conventional ELISA and high-sensitivity PCR-based ELISA were used to measure interleukin levels.
• RT-qPCR and immunohistochemistry were employed for gene and protein validation.
• Plasma, sera, and EBCs from NSCLC patients and healthy volunteers were analyzed.

Main Results:

• IL-11 was significantly elevated in NSCLC patient plasma compared to controls (p < 0.0001).
• IL-11 was undetectable in sera and EBCs using conventional ELISA.
• IL-11 gene and protein upregulation was confirmed in NSCLC tumors.
• IL-6, IL-8, IL-17A, and IL-33 lacked detection sensitivity, indicating a need for improved assays.
• Discrepancies were observed between paired plasma and serum biomarker concentrations.

Conclusions:

• IL-11 shows promise as a plasma biomarker for NSCLC, but detection sensitivity needs optimization.
• Current assays are insufficient for detecting IL-6, IL-8, IL-17A, and IL-33 in the studied samples.
• Caution is advised against relying on a single type of blood sample for biomarker assessment.
• Further research should focus on enhancing assay sensitivity and exploring diverse sample matrices for NSCLC biomarker discovery.